Serological diagnosis of Epstein-Barr virus infection: Problems and solutions

Massimo De Paschale, Pierangelo Clerici

Abstract

Serological tests for antibodies specific for Epstein-Barr virus (EBV) antigens are frequently used to define infection status and for the differential diagnosis of other pathogens responsible for mononucleosis syndrome. Using only three parameters [viral capsid antigen (VCA) IgG, VCA IgM and EBV nuclear antigen (EBNA)-1 IgG], it is normally possible to distinguish acute from past infection: the presence of VCA IgM and VCA IgG without EBNA-1 IgG indicates acute infection, whereas the presence of VCA IgG and EBNA-1 IgG without VCA IgM is typical of past infection. However, serological findings may sometimes be difficult to interpret as VCA IgG can be present without VCA IgM or EBNA-1 IgG in cases of acute or past infection, or all the three parameters may be detected simultaneously in the case of recent infection or during the course of reactivation. A profile of isolated EBNA-1 IgG may also create some doubts. In order to interpret these patterns correctly, it is necessary to determine IgG avidity, identify anti-EBV IgG and IgM antibodies by immunoblotting, and look for heterophile antibodies, anti-EA (D) antibodies or viral genome using molecular biology methods. These tests make it possible to define the status of the infection and solve any problems that may arise in routine laboratory practice.

Key words: Epstein-Barr virus infection; Serology; Immunoblotting; Avidity IgG; Epstein-Barr virus-DNA

INTRODUCTION

Epstein-Barr virus (EBV) or human herpesvirus 4 is ubiquitous, and about 90% of adults throughout the world have antibodies against it[1]. Acute infection is usually asymptomatic in immunocompetent children, and manifests itself as mononucleosis in 30%-50% of immunocompetent adolescents and adults[2,3]. Especially in immunocompromised patients, EBV is associated with various lymphoproliferative disorders and some neoplastic diseases, including Burkitt's lymphoma and nasopharyngeal carcinoma.

Like other herpesviruses, EBV has a productive lytic cycle and a latent phase. B lymphocytes are infected after the viral envelope glycoprotein gp350/220 has bound to the CD21 cell receptor, which is also the receptor for the C3d component of complement[4]. During the lytic cycle, regulatory proteins belonging to the immediately early antigen (IEA) and early antigen (EA) groups are synthesized to allow the production of viral DNA (EBV-DNA), the virion structural proteins (viral capsid antigen, VCA) and membrane proteins (MA). The lytic cycle leads to the destruction of infected cells and the production of viral particles, but EBV can also persist in host cells without complete virus production by replicating ex-
trichromosomal nucleic acids (episomes) following the expression of a few selected viral genes. The expression of these genes leads to the immortalization of B cells and their transformation into proliferating blasts. In immunocompetent patients, cytotoxic T lymphocytes and NK cells control the growth of transformed cells during primary infection, particularly the CD8+ T cells directed against antigens of the lytic cycle. These cells are also directed against antigens of the latent phase, but the response is insufficient to ensure their complete eradication, and the virus can persist throughout life with low or intermittent levels of virion production. After recovery, it has been estimated that about 1 in 10000-100000 memory cells contain EBV DNA in episomal form. During the latent phase, EBV nuclear antigens (EBNAs) and three latent membrane proteins (LMPs) are expressed in infected cells. EBNAs represent a complex of at least six proteins (EBNA 1-6). EBNA-1 is responsible for maintaining the episomal state of EBV DNA in infected cells, and EBNA-2 seems to be involved in the immortalization of B lymphocytes. The LMPs (LMP1, LMP2A and LMP2B) may also play a role in the process of immortalization, and oncoprotein LMP-1 appears to be responsible for most of the effects altering the growth of infected B cells. Depending on the expressed antigens, it is possible to distinguish four types of latency, each of which is typical of the diseases associated with EBV (Table 1). As EBNA-3 is a target of CD8+ lymphocytes, latent cells are normally eliminated by cytotoxic T lymphocytes in immunocompetent patients, whereas the transformed cells can proliferate and cause various lymphoproliferative disorders in immunosuppressed patients.

Reactivation of the lytic cycle may occur during latency, possibly because of the recirculation of infected memory B cells in lymphoid tissues, which, stimulated by their natural antigens, differentiate into plasma cells. The beginning of the replication cycle is characterized by the initial expression of the BZLF1 gene, the expression of the latent membrane protein 1, and the production of a trichromosomal genome consisting of at least six EBV nuclear antigens (EBNA). EBNA-1 is responsible for maintaining the episomal state of EBV DNA in infected cells, and EBNA-2 seems to be involved in the immortalization of B lymphocytes. The LMPs (LMP1, LMP2A and LMP2B) may also play a role in the process of immortalization, and oncoprotein LMP-1 appears to be responsible for most of the effects altering the growth of infected B cells. Depending on the expressed antigens, it is possible to distinguish four types of latency, each of which is typical of the diseases associated with EBV (Table 1). As EBNA-3 is a target of CD8+ lymphocytes, latent cells are normally eliminated by cytotoxic T lymphocytes in immunocompetent patients, whereas the transformed cells can proliferate and cause various lymphoproliferative disorders in immunosuppressed patients.

Anti-MA antibodies seem to be particularly important in limiting the spread of infection and preventing reinfections. The membrane antigen consists of three glycoproteins (gp 350, gp 250 and gp 85), which are present on the viral envelope and the membranes of infected cells, and mediate the cell binding of the virus.

Antibodies against the capsid antigen IgG (VCA IgG) typically appear at the time of the onset of the clinical symptoms of acute infection, and remain positive for life, whereas IgG antibodies (VCA IgG) usually appear at the same time as VCA IgG and disappear within a few weeks, although they may persist for several months. Children and adults with primary infection are not always positive for VCA IgG, and VCA IgM is typically negative in the first 3-4 weeks after the onset of clinical symptoms, and is therefore indicative of past infection. Furthermore, most patients with chronic infection and immunosuppressed patients are negative for VCA IgM and VCA IgG.

Antibodies against EBNA-1 IgG (EBNA-1 IgG) appear early, and may be present in up to 30% of the patients in the course of disease, whereas anti-EBNA-1 IgG (EBNA-1 IgG) is usually undetectable during the first 3-4 weeks after the onset of clinical symptoms, and is therefore indicative of past infection. Furthermore, most patients with chronic infection and immunosuppressed patients are negative for EBNA-1 IgG, and VCA IgG.

Searching for all of these antibodies is a means of defining infection status and can also help in the differential diagnosis as mononucleosis syndrome may be caused by other pathogens such as rubella, mumps, HHV 6, HCMV, HIV, Toxoplasma gondii, etc.

Using only three parameters (VCA IgG, VCA IgM and EBNA-1 IgG), it is generally easy to distinguish acute and past infections in immunocompetent patients. The presence of VCA IgG and VCA IgM in the absence of EBNA-1 IgG indicates acute infection, and the presence of VCA IgG and EBNA-1 IgG in the absence of VCA IgM is typical of past infection (Table 2). However, some cases may have different profiles that can create diagnostic doubts, such as the presence of VCA IgM in the absence of VCA IgG and EBNA-1 IgG, the simultaneous presence of VCA IgG, VCA IgM and EBNA-1 IgG, and the presence of EBNA-1 IgG in the absence of VCA IgG.
Table 1  Types of latency in Epstein-Barr virus-associated diseases

| Type | Description | Examples |
|------|-------------|----------|
| Type 0 latency | (EBERs, BARTs) | AIDS-related plasmablastic lymphoma |
| Type I latency | (EBNA1, LMP2, EBERs, BARTs) (BamHI A rightward fragments) | Burkitt’s lymphoma |
| Type II latency | (EBNA1, LMP1, LMP2, EBERs, BARTs) | Hodgkin’s lymphoma, AIDS-related Burkitt’s lymphoma or primary effusion lymphoma |
| Type III latency | (EBNA1, -2, -3A, -3B, -3C; LMP1, LMP2, EBERs, BARTs) | Peripheral T cell lymphoma, NK/T cell lymphoma, nasal type |

Table 2  Interpretation of Epstein-Barr virus serological profiles in immunocompetent patients

| Anti-EBV antibodies | Interpretation |
|---------------------|---------------|
| VCA IgM  | VCA IgG  | EBNA-1 IgG |
| Negative | Negative | Negative | No immunity |
| Positive | Negative | Negative | Acute infection or non-specificity1 |
| Positive | Positive | Negative | Acute infection |
| Negative | Positive | Positive | Past infection |
| Positive | Positive | Positive | Late primary infection or reactivation1 |
| Negative | Negative | Positive | Past infection or non-specificity1 |

1Further testing required.

and IgM (Table 2). In such circumstances, in addition to following up the patients to assess any changes in the antibody profile, it is also useful to perform other laboratory tests.

The detection of antibodies is less useful in immunocompromised patients because of their immune system dysfunctions, and the fact that the type of antibody and its maintenance may vary over time depending on the dynamics of the disease, thus leading to atypical profiles.

There is generally an increase in the titers of VCA IgG and EA (D) or EA (R) IgG, with a decrease in the titer or loss of EBNA-1 IgG; there may also be increases in other antibody classes such as EA IgA and, although less frequently, VCA IgM. The variability observed in different patients (this may be complicated by the therapeutic use of immunoglobulins) indicated that a search for EBV DNA by molecular biology methods is useful for the diagnosis and follow-up of patients at risk of developing EBV-related lymphoproliferative disorders.

Serology is generally not decisive also in patients with EBV-associated tumors as high values of VCA IgG and EA IgG may persist with low titers of EBNA-1 IgG (Table 3) and, once again, a search for EBV DNA is essential. There is one type of EBV-related cancer whose serology is characteristic: nasopharyngeal carcinoma typically leads to high VCA and EA IgA levels as a result of its origin on the nasopharyngeal mucous membrane.

LABORATORY METHODS

Various laboratory tests have been used to diagnose EBV infection. In addition to tests for other diagnostically useful parameters (leukocytosis, lymphocytosis with atypical lymphocytes, abnormal liver function test, etc), there are tests for detecting non-specific heterophile antibodies and specific anti-EBV antibodies, as well as molecular biology methods used to detect EBV DNA.

Heterophile antibodies

Heterophile antibodies are antibodies that agglutinate cells of other animal species that are mainly associated with mononucleosis due to EBV but may be, albeit rarely, also detected in other diseases. They peak 2-5 wk after symptom onset and then decline rapidly, although they may rarely persist for 6-12 mo. Between 85% and 90% of adolescents and adults are positive during the course of EBV infection: about 50% in the first week, and 60%-90% in the second and third. However, only 50% of children aged 2-5 years are positive at any time during the course of infection, and only 10%-30% of those aged less than 2 years. The rate of false negative results can therefore be high in young children, whereas false positive results are observed in only 2%-3% of the patients with autoimmune diseases.

Despite these limitations, detecting heterophile antibodies can be helpful in the case of primary infection mainly because of the simplicity of the tests. In routine clinical practice, these include agglutination tests using sheep, goat or horse red blood cells as antigens after absorption with guinea pig kidney extracts in order to remove natural antibodies against Forssman antigen (the Paul Bunnel reaction), and newer tests based on latex particles with adherent specific bovine antigen for heterophile antibodies (monospot assays). Recently, multiplex flow immunoassays (MFI) have been proposed because

---

Andrea A, et al. De Paschale M et al. Epstein-Barr virus serological diagnosis. In press.
they are more sensitive in the case of acute infections\cite{49}. However, given the level of false negative results, negative findings need to be followed by a search for specific antibodies\cite{2,48}.

**Specific EBV antibodies**

The specific tests for anti-EBV antibodies use different substrates or antigens and various technologies, of which those commonly used for the routine screening of EA IgG, EBNA-1 IgG, VCA IgG and IgM are immunofluorescence assays (IFAs) or enzyme immunoassay (EIAs) with enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassay (CLIA) versions or newer multiplex flow immunoassay (MFI). IFAs usually use EBV-transformed B cell lines from patients with Burkitt’s lymphoma (e.g. the P3HR-1 or Raj cell lines)\cite{2,23,46,50-52}, whereas EIAs use purified native or recombinant proteins, synthetic peptides or fusion proteins (complete proteins or fragments of the proteins encoded by the EBV genes)\cite{42,48}. The type and preparation of the antigens used are probably responsible for the differences in the sensitivity and specificity of the various assays\cite{42,53,54}. IFA has been used as the reference method, although its sensitivity is the same as or less than that of EIAs\cite{43}, automated versions of which allow a large number of samples to be tested and are commonly used in laboratories with a large routine workload. The latest CLIA tests using synthetic peptides with different cut-off values for VCA IgM and EBNA-1 IgG can better distinguish the stage of infection\cite{42} and, in the case of samples that are simultaneously EBNA-1 IgG, VCA IgG and IgM positive, may help distinguish recent (transient phase) and past infection or reactivation\cite{45,46}.

**Immunoblotting**

In order to confirm the screening assays, various immunoblotting tests have been developed using viral lysates of EBV-transformed cells and recombinant antigens (line blots)\cite{23}. It is considered that the latter is unaffected by antibodies against the cell material that can be found in patients with mononucleosis\cite{23,58}. Some line blots use recombinant antigens coated on the solid phase, such as EBNA-1 (p72), VCA (p18 and p23), EA (p54 and p138) and MA (gp 350/250); the most recent also use IEA (ZEBRA). It has been reported that the sera of patients with acute infection show anti-p23 IgG, anti-p55 IgG and anti-p138 IgG, but not anti-p72 IgG, whereas the sera from patients with past infection show anti-p23 IgG, anti-p72 IgG and anti-p18 IgG\cite{12}. Kinetic studies have found that a strong IgG response to p72 is not observed until 20 d after disease onset. As anti-p72 IgG and anti-p18 IgG are present in patients with past infection, but not in those with acute infection\cite{23}, anti-p18 IgG can be considered equivalent to EBNA-1 IgG in terms of significance. In addition, as anti-p18 IgG is not lost in the case of immunosuppression\cite{23}, immunoblotting is especially useful in distinguishing acute and past infections in cases that are VCA IgG positive, but EBNA-1 IgG and VCA IgM negative.

Immunoblots for IgM have also been developed to detect VCA IgM in patients with acute infection, but not anti-p72 IgM\cite{48}, which may be useful for confirming the specificity of the VCA IgM detected by screening assays.

**IgG avidity**

The IgG avidity test can assess the degree of IgG maturation. Avidity is low at the beginning of an acute infection, but increases when the immune response matures\cite{39,41}. For example, the maturation kinetics of VCA IgG last several weeks and in some cases up to 3 mo after symptom onset\cite{32,63}. Avidity can be measured using an ELA, IFA or immunoblotting\cite{23,57,63}. Two aliquots of the same sample are tested in parallel for the presence of IgG antibodies: one is not treated, and the other is treated with substances that dissociate the antibodies from the antigens (usually 8 M urea). Since the dissociation depends on antibody avidity, the ratio between the treated and untreated sample defines the degree of avidity. A search for avidity can therefore be used to estimate the duration of a primary infection, and differentiate acute and past infection\cite{23,57,63,65}.

The published data depend on the examined antibody and therefore the type of antigen used for the test. In addition to a mix of antigens, it is possible to use the whole or specific VCA (p23 or p18), IEA (ZEBRA), EA (p138 or p54) or EBNA (p72). Avidity varies depending on the kinetics of the various antibodies\cite{63,60}, e.g. in VCA IgG, it has been reported that avidity is low in the samples collected during the first 12 wk after symptom onset, thus indicating recent infection\cite{67}. With the passing of time, the avidity of VCA IgG may become borderline or high when the avidity of EA IgG is still low\cite{63}. Immunoblotting, which has various antigens coated on the solid phase, can be used to visualize the avidity of various antibodies simultaneously (Table 4), although the maturation of anti-IEA and EA antibodies (BZLF1, p138 and p54) does not seem to indicate immune status as antibodies with a low degree of avidity can be found even during reactivation. Consequently, the manufacturer points

---

Table 3: Serological profiles in Epstein-Barr virus reactivation and some Epstein-Barr virus-associated diseases

| Diseases                  | VCA IgM | VCA IgG | VCA IgA | EA (D) IgG | EA (R) IgG | EA IgA | EBNA1 IgG |
|---------------------------|---------|---------|---------|------------|------------|--------|-----------|
| Choronic active infection | +/−     | ++      | +/−     | +          | +         | +      | +/−       |
| Burkitt’s lymphoma        |         | ++      |         | +          | +/−        |        | +         |
| Nasopharyngeal carcinoma  | −       | ++      | −/−     | +          | ++        | +      | −/−       |
| Hodgkin’s lymphoma        | −       | ++      | −       | +          | −         | −      | +         |
| Reactivation              | +/−     | ++      | +/−     | +          | +/−       | −      | +/−       |

---
Table 4 Interpretation of IgG avidity test with immunoblotting

| IgG         | IgG avidity                        | Interpretation            |
|-------------|------------------------------------|---------------------------|
| Negative    | Not observed                        | No infection              |
| Positive    | Low-high avidity for BZLF1 and/or p138 and/or p54 | Acute infection |
|             | Low avidity for p23                 | Acute infection           |
|             | High avidity for p23                | Recent infection          |
|             | Low-intermediate avidity for p18 and p23 | Recent infection |
|             | Low-high avidity for EBNA-1 and/or p18, and possible high avidity for p23 | Past infection |

out that a reduction in the intensity of the EA and IEA bands alone is not an index of recent infection\[48\].

The limitations of avidity testing are the individual maturation rates of antibodies and the fact that the tests cannot be used in newborns because of the presence of maternal antibodies.

Molecular biology

A number of different methods, techniques and protocols have been used to determine the presence of EBV DNA and measure viral load\[69-72\]. Dot blotting, Southern blotting, PCR and in situ hybridization have all been applied to various materials, but their differences in sensitivity and specificity have led to the results that need to be considered cautiously\[28\] as they vary from laboratory to laboratory\[74,75\]. More recent studies indicate that real-time PCR is particularly sensitive\[28\] and very useful for defining infection status, especially in immunocompromised patients\[45,75,76\] and those at risk of developing EBV-related disorders\[45\]. However, there is still no consensus concerning the best material to use, units of measurement, or the quantitative levels requiring intervention or predicting prognosis\[16,74,77,79\]. This means that particular care is necessary when comparing the data of different studies\[79\]; for example, the units of measurement include copies per milliliter, copies per microgram of DNA, copies per 100,000 leukocytes, and copies per positive cell\[79\]. The targets used may also vary from one method to another: LMP2, BKRF1 or BamHI-W (EBNA-1), BNRF1 (membrane protein), BXLF1 (thymidine kinase), BZLF1 (ZEBRA), BALF5 (viral DNA polymerase) or BHFRF-1 (transmembrane protein).

Furthermore, there is much debate concerning the material that should be used to search for EBV DNA, such as whole blood, peripheral blood mononuclear cells (PBMCs), plasma or serum\[13,80\]. There is also the problem that incorrectly stored whole blood can cause EBV DNA to leave the intracellular compartment and give rise to false positive results in plasma or serum, and false negative results may be due to nucleases that are capable of partially degrading plasma EBV DNA\[81\].

In general, the best material used to search for EBV DNA depends on where it is, and varies during the course of the disease\[13\]. The virions produced during primary infection spread in peripheral blood\[82-83\], and it is also possible to determine the EBV-free or fragmented DNA coming from apoptotic cells\[83\], and the B cells transformed during the latent phase also pass into the bloodstream. EBV DNA can therefore be determined in serum or plasma as well as in PBMCs\[84\]. In patients with primary infection, it is frequently detected in whole blood (PBMCs and plasma/serum) within 14 d of symptom onset\[85-89\]. After the initiation of an immune response, viral load decreases slowly in PBMCs, but rapidly in plasma/serum, and it becomes undetectable after 3-4 wk\[85-89\], whereas memory cells with EBV may remain latent for a long time in blood. However, it must be kept in mind that there may be individual variations due to individual differences in kinetics, and viral load may increase after an initial decline, and in some cases, it may take as long as a year or more before it reaches stably low levels. Finally, even when this level is reached, the blood of a healthy carrier contains 1-50 copies of EBV DNA per million white blood cells, whereas EBV-DNA is almost always undetectable in plasma or serum\[82,83-90\]. The presence of plasma/serum EBV-DNA is therefore considered a sign of primary infection\[13\] or reactivation, and the viral load correlates with disease severity\[85,88,89\]. A search for EBV DNA may be more sensitive than serology in the early stages of the disease\[89\], and some studies have found that it correlates better with clinical acute infection than the avidity of VCA IgG\[46\]. However, in immunocompromised patients with acute infection, it is not usually necessary to look for EBV DNA as serology is sufficient except in cases with negative or doubtful serological findings in which there is a strong clinical suspicion of infection\[93\].

A search for EBV DNA is particularly important in immunocompromised patients with an incomplete humoral response and patients who have received transfusions or immunoglobulins that confound serological test results\[28\]. It has been reported that immunocompromised patients have higher baseline viral levels than healthy carriers\[99,100\], which decline after treatment. A search for EBV DNA is also useful in patients with EBV-related tumors, except for those with AIDS-related brain tumors in whom the blood levels are low because of the blood-brain barrier\[99,101\]. In EBV-related cancers, episomal or naked EBV DNA from apoptotic tumor cells is found...
EBV: Epstein-Barr virus.

in serum and plasma[84,102], which may also contain tumor cells with latent EBV infection[13] and virions from a small number of tumor cells undergoing lytic infection. The most suitable material varies with the tumor[13] and depends on where EBV DNA is mainly found during the course of the disease (PBMCs or serum/plasma).

**ATYPICAL PROFILES IN IMMUNOCOMPETENT PATIENTS**

The presence of VCA IgG and IgM in the absence of EBNA-1 IgG indicates acute infection, whereas the presence of VCA IgG and EBNA-1 IgG in the absence of VCA IgM is typical of past infection. These profiles cover the vast majority of situations found in routine laboratory practice. However, the profile of a minority of cases may give rise to doubts or require confirmation.

**Isolated VCA IgM**

VCA IgM usually appears at the same time as VCA IgG, but because they can be detected earlier, a profile of isolated VCA IgM is usually thought to indicate an early stage of acute infection. Nevertheless, it is recommended to assess the specificity of the result because it may be made aspecific by interfering rheumatoid factor and autoantibodies, or cross-reacting factors such as HCMV or parvovirus B19[67]. A search for these factors and immunoblottting for IgM may be as helpful as the determination of other parameters of acute infection such as heterophilic antibodies or HBV DNA[90]. A search for anti-EA (D) IgG can also be useful as about 85% of the patients with acute infection are positive for these antibodies for up to 3 mo after the onset of symptoms[23,34].

**Isolated VCA IgG**

In some cases, VCA IgM may not be produced or appear 1-2 wk after VCA IgG, or present for a very short time or at low concentrations and it may not be detected by conventional tests[23,32,103,104]. In addition, about 5% of the patients do not produce EBNA-1 IgG after EBV infection[103,108] or their levels remain below the limit of detection[157,258]. Furthermore, even when they are produced, they may be lost over time particularly, but not exclusively, in immunocompromised patients[23,103,106]. Consequently, isolated VCA IgG may be found in cases of past infection with the loss or disappearance of EBNA-1 IgG, as well as in cases of acute infection with the delayed or early disappearance of VCA IgM. This pattern can be found in approximately 7% of cases in routine laboratory practice and in about 8% of all subjects with at least one marker of EBV infection; it also tends to become more frequent with advancing age[107].

Such cases require further diagnostic investigations (Table 5), including immunoblottting for IgG, avidity tests for VCA IgG, searches for viral genome, or heterophile antibodies or EA (D) IgG[64,105], or a repetition of the test after about 30 d in order to identify any change in the antibody profile. However, this last option inevitably delays the diagnosis until the second sample is collected, and physicians tend to avoid it if the symptoms improve over time, especially in the case of children, they may find it traumatic, which means the second sampling usually involves only a small number of patients[100]

| Tests                              | Advantages                                                                 | Disadvantages                                                                 |
|-----------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| EBV IgG immunoblotting            | Useful in distinguishing acute from past infection                      | Individual antibody production; expensive                                   |
| IgG avidity                       | Useful in distinguishing acute from past infection                      | Individual maturation. Not useful in newborns                               |
| Molecular biology                 | Useful in distinguishing acute from past infection                      | Uncorrected conservation of blood sample, presence of nucleasis; expensive; organisational problems |
| Heterophile antibodies            | Useful in distinguishing acute from past infection if positive; inexpensive and simple | Not very sensitive (especially in children)                                 |
| Anti-EA(D) IgG                    | Of some use in distinguishing acute from past infection; costs the same as a screening test | Not useful in at least 10% of cases                                          |

**Table 5 Additional tests in the case of an isolated viral capsid antigen IgG pattern**
Table 6  Additional tests in the case of a simultaneous Epstein-Barr virus nuclear antigen 1 IgG, viral capsid antigen IgG and IgM positive pattern

| Tests                          | Advantages                                         | Disadvantages                                                                 |
|-------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------|
| EBV IgM immunoblotting        | Useful only in verifying the specificity of EBV IgM| Not useful in distinguishing late primary infection (transient) from reactivation; expensive |
| HCMV IgM                      | Useful in verifying the specificity of EBV IgM     | Not useful in distinguishing late primary infection (transient) from reactivation |
| Parvovirus IgM                | Only useful in verifying the specificity of EBNA-1 IgG| Not useful in distinguishing late primary infection (transient) from reactivation; expensive |
| EBV IgG immunoblotting        | Useful in distinguishing primary infection (transient) from reactivation| Individual maturation |
| IgG avidity                   | Useful in distinguishing primary infection (transient) from reactivation| Individual maturation |
| Molecular biology             | Useful for EBV reactivation follow-up              | Difficult to distinguish late primary infection (transient) from reactivation in a single sample; expensive; organisational problems |
| Heterophile antibodies        | Useful in distinguishing late primary infection (transient) reactivation when positive; inexpensive and simple| Not very sensitive (especially in children) |
| Anti-EA(D) IgG                | Useful for EBV reactivation follow-up              | Not useful in distinguishing late primary infection (transient) from reactivation in a single sample; expensive |
| CLIA for EBV antibodies with differential cut-off values | Useful in distinguishing primary infection (transient) from past infection; can be used for screening| Requires further study |

EBV: Epstein-Barr virus; EBNA: EBV nuclear antigen; CLIA: Chemiluminescence immunoassay.

**Simultaneous presence of EBNA-1 IgG, VCA IgG and VCA IgM**

VCA IgM may persist for several months after an acute infection[35], and may also reappear during EBV reactivation[33,112]. Consequently, EBNA-1 IgG, and VCA IgG and IgM may be simultaneously present in patients with primary EBV infection if VCA IgM persist and EBNA-1 IgG have already been produced (a phase that has been variously defined as “recent infection”, “primary infection, transient phase or convalescence”, “past infection, IgM persisting”), or in those with reactivation and the simultaneous presence of VCA IgM and EBNA-1 IgG[42]. Reactivation is still relatively rare and often short in immunocompetent subjects, and is generally considered of no clinical relevance[113,114]; however, it can cause serious complications in immunocompromised patients.

This serological pattern is uncommon (approximately 5% in normal routine laboratory practice)[32], and further diagnostic tests are needed to distinguish transient infection and reactivation (Table 6). First of all, it is important to verify the specificity of VCA IgM because there may be false positive results[115-117] during the course of infection with other pathogens, such as HCMV, parvovirus B19, Toxoplasma gondii, hepatitis A or HIV[118-120]. It has been shown that primary HCMV infection often causes a further antibody response in anti-EBV IgM[125], and cross-reactive antibody responses against conserved epitopes are well known among herpes viruses, such as the glycine-alanine epitope shared by EBV and HCMV[87]. It has also been shown that primary HCMV infection often causes a further antibody response in anti-EBV IgM[125], and cross-reactive antibody responses against conserved epitopes are well known among herpes viruses, such as the glycine-alanine epitope shared by EBV and HCMV[87].
some cases\[^{98}\] Moreover, as false positive reactions may also result from the presence of autoantibodies or rheumatoid factor, it can be useful to look for these interfering factors. However, it needs to be pointed out that cold agglutinins, rheumatoid factor and autoantibodies can be found for a short period during the course of EBV mononucleosis because of the polyclonal activation of B-cells\[^{128}\], therefore, the presence of rheumatoid factor does not automatically mean a falsely positive VCA IgM result. Finally, EBNA-1 IgG positivity in patients with primary infection may also result from aspecific reactivity, which can be detected by immunoblotting for IgG antibodies\[^{124}\]. Furthermore, the recently developed ELA for antibodies to EBNA-1 IgG based on recombinant or synthetic peptides may be more sensitive than its predecessors, and allow their identification early in the course of primary EBV infection\[^{126}\].

Once the specificity of the results obtained has been established, additional diagnostic approaches are necessary (Table 6). In addition to repeating the test after a reasonable period of time in order to detect any changes in the antibody profile, VCA IgG avidity has proved to be particularly useful because low levels of avidity have been found in the course of recent infection, and high levels in the course of past infection or reactivation\[^{62-64}\]. Some studies have found that fewer than half of immunocompetent patients with this profile and a low degree of avidity have primary infection, and about 20% or less was a reactivation that is probably clinically insignificant\[^{112,124}\].

In order to fully understand the IgG avidity test and evaluate the results in relation to antibody maturation time, it is important to know how long after the onset of symptoms the blood sample was taken.

The use of heterophile antibodies is controversial because some studies have shown that they are very sensitive (94% of infected patients with transient infection)\[^{128}\] whereas others have found very few cases of simultaneous positivity for EBNA-1 IgG, VCA IgG, VCA IgM and heterophile antibodies\[^{109}\].

The use of molecular biology seems to be a rather delicate question. Patients with latent infection have an almost constant number of circulating infected B cells in peripheral blood and, in the case of reactivation, these differentiate into plasma cells, leading to the start of the replicative cycle and increased EBV DNA levels in PBMCs and serum/plasma. It has been reported that a search for EBV DNA in PBMCs and serum/plasma is important for an immediate diagnosis of reactivation but, although this is true in the patients who are followed up over time in order to detect any changes in viral load, the finding of EBV DNA in a single sample should not necessarily be seen as a sign of reactivation\[^{99}\]. Consequently, as EBV DNA is present in cases of reactivation or primary infection, it is unlikely that testing one sample will be able to distinguish the two situations\[^{59,96}\].

Persistent or reactivated EBV infection is characterized by high titers of EA (D) IgG, especially in immunocompromised patients\[^{26,29}\]. After reactivation, the levels of these antibodies increase with VCA IgG, whereas the levels of EBNA-1 IgG decrease. An increase in the titer of EA (D) IgG can therefore be considered a useful marker of reactivation. However, as EA (D) IgG can also be found in 85% of primary infections and 20%-30% of past infections, and simultaneous VCA IgM, VCA IgG, EBNA-1 IgG and EA (D) IgG positivity has been seen in both the transient phase and reactivation\[^{76}\], the detection of anti-EA (D) IgG seems to be useful only if serial sampling is possible. Other antibodies have been found in cases of reactivation. It has been suggested that EBNA IgM may be useful in identifying reactivation\[^{114}\]. The combination of negative EBNA IgG and positive EBNA IgM, in addition to a high degree of avidity for VCA IgG within 3 mo of an acute infection, should reliably indicate reactivation rather than primary EBV infection\[^{95}\].

It has also been suggested that VCA IgA may be a marker of reactivation. These antibodies reach a peak level 3-4 wk after primary infection and decline slowly, but may last indefinitely. Different studies have found them in 35%-74% of acute cases\[^{34,127,128}\] but they were also seen in 10% of healthy subjects. High levels were also found in patients with immunodeficiencies, recurrent parotitis, multiple sclerosis or nasopharyngeal cancer, as well as in pregnant women and elderly subjects\[^{26,129,132}\]. Consequently, a search for VCA IgA is considered useful only in the diagnosis and management of patients with nasopharyngeal carcinoma\[^{133,134}\].

EA (R) IgG, EA IgM, EA IgA, VCA IgG-3 and the EBNA-1/EBNA-2 ratio have also been used as markers of reactivation in some studies\[^{134,135,137,139}\] but, as many of these antibodies are also present in primary infections, and some even in past infections, the usefulness of a single sample in patients with the simultaneous presence of EBNA-1 IgG, VCA IgG and IgM has yet to be evaluated.

Finally, the use of different cut-off values proposed by the most recent CLIAs for determining VCA IgG, VCA IgM and IgG EBNA-1 in parallel seems to be a promising approach as it should make it possible to distinguish the different stages of EBV infection, especially the difference between transient infection and past infection or reactivation\[^{53,56}\].

**Isolated EBNA-1 IgG**

VCA IgM usually appears at the same time as VCA IgG antibodies, but they disappear completely within a few weeks\[^{32,37}\], whereas patients are VCA IgG positive for the rest of their lives\[^{81}\]. EBNA-1 IgG cannot usually be detected during the first 3-4 wk after the onset of clinical symptoms\[^{32,140}\] and as VCA IgG antibodies persist but EBNA-1 IgG antibodies may disappear, especially in the case of immunosuppression\[^{67}\], a pattern of isolated VCA IgG without VCA IgM or EBNA-1 IgG has been widely documented as mentioned above, whereas the presence of EBNA-1 IgG without VCA IgG is generally considered implausible\[^{3}\]. However, some immunoblotting studies have found that 2% of subjects who have
CONCLUSION

A number of tests have recently been developed that may help clarify doubtful results in the serological diagnosis of EBV infection, and it is now possible to reach a conclusion without having to wait for a second sample taken after a certain lapse of time. What tests should be used after screening depends on various factors in addition to their scientific and technical suitability; these include organizational and economic questions (such as differences in costs and the reimbursements foreseen by the National Health Service or insurance companies), as well as the availability of space and adequately trained personnel. Furthermore, the number of routine tests (the number of samples with inconclusive results) affects the decision to undertake further more or less expensive laboratory tests or to send the sample (or the patient) to a reference laboratory. Finally, the type of patient may also be decisive. If the laboratory has to deal not only with samples from immunocompetent patients, but also with samples from immunosuppressed patients and/or patients with other EBV-related diseases, the choice of methods should privilege those suitable for all patients.

In conclusion, considerable progress has been made in the serological diagnosis of EBV infection and, using appropriate algorithms and methodologies, it is possible to solve all of the problems that may arise during the course of routine laboratory practice.

REFERENCES

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001: 2575-2627
2. Lennette ET. Epstein-Barr virus (EBV). In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. Washington: American Public Health Association, 1995: 299-312
3. Steven NM. Infectious mononucleosis. EBRV Reports 1996; 3: 91-95
4. Fingerhut JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984; 81: 4510-4514
5. Niedobitek G, Hamilton-Dutoit S, Herbst H, Finn T, Yetner M, Pallesen G, Stein H. Identification of Epstein-Barr virus-infected cells in tonsils of acute infectious mononucleosis by in situ hybridization. Hum Pathol 1989; 20: 796-799
6. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68: 7374-7385
7. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Ann Rev Immunol 2007; 25: 587-617
8. Callan MF, Tan L, Annels N, Oggs GS, Wilson JD, O’Callaghan CA, Steven N, McMichael AJ, Rickinson AB. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr Virus in vivo. J Exp Med 1998; 179: 1395-1402
9. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35-42
10. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337
11. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 2000; 10: 83-100
12. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, editors. Virology. New York: Raven Press, 1990: 1889-1920
13. Kimura H, Ito Y, Suzukiere, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 2008; 18: 305-319
14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1: 75-82
15. Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118: 45-58
16. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008; 10: 279-292
17. Babel N, Schwarzmann F, Prang N, Jaeger M, Wolf H, Kern F, Volk HD, Reinke F. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72: 736-739
18. Horwitz CA, Henle W, Henle G, Schmitz H. Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med 1975; 58: 330-338
19. Preiksaitis JK, Diaz-Mitoma F, Mirazynas F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986-994
20. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103
21. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, Bucsky P. Patients at risk for development of posttransplant
lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr virus viral load by using real-time quantitative polymerase chain reaction. *Transplantation* 2001; 72: 1012-1019.

22. *Wandinger K, Jabs W, Siekhaus A, Bube S, Trillenberg P, Wagner H, Wessel K, Kirchner H, Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology* 2000; 55: 178-184.

23. *Bauer G. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab 2001; 47: 223-230.*

24. *Lennette E, Henle W. Epstein-Barr virus infections: clinical and serological features. Lab Med* 1987; 25: 23-26.

25. *Wohlrabe P, Färber I, Wutzler P, Uhlig R. Antibodies to Epstein-Barr virus-induced early antigens in blood donors. Acta Virol* 1989; 33: 344-348.

26. *Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res* 1981; 41: 4222-4225.

27. *Coyle PV, Wyatt D, Connolly JH, Lynch GA. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma in Northern Ireland. Ir J Med Sci 1987; 156: 182-184.*

28. *Jenson HB. Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis. Curr Infect Dis Rep* 2004; 6: 200-207.

29. *Bennett NJ, Domachowska J. Pediatric Mononucleosis and Epstein-Barr virus infection. eMedicine from WebMD. Updated October 12, 2010. Available from: URL: http://emedicine.medscape.com/article/963894-overview.*

30. *Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 1980; 77: 2979-2983.*

31. *Thorley-Lawson DA, Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci USA 1980; 77: 5307-5311.*

32. *Schilling M, Kampmann M, Henning M, Murray G, Hanselmann I, Bauer G. Variability of humoral immune response to acute Epstein-Barr virus (EBV) infection: evaluation of the significance of serological markers. Med Microbiol Lett* 1993; 2: 296-303.

33. *Schmitz H, Volz D, Krainick-Riechert C, Scherer M. Acute Epstein-Barr virus infections in children. Med Microbiol Immunol* 1992; 181: 58-63.

34. *Nikoskelainen J, Neel EU, Stevens DA. Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J Clin Microbiol* 1979; 10: 75-79.

35. *Evans AS, Niederman JC, Cenabre LC, West B, Richards VA. A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody. J Infect Dis 1975; 132: 546-554.*

36. *Fleisher G, Henle W, Henle G, Lennette ET, Biggar RJ. Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J Infect Dis 1979; 139: 553-558.*

37. *Lamy ME, Favor AM, Cornu C, Mendez M, Segas M, Burtonboy G. Study of Epstein Barr virus (EBV) antibodies: IgG and IgM anti-VCA, IgG anti-EA and Ig anti-EBNA obtained with an original microtiter technique: serological criterions of primary and recurrent EBV infections and follow-up of infectious mononucleosis-seroepidemiology of EBV in Belgium based on 5178 sera from patients. Acta Clin Belg* 1982; 37: 281-298.

38. *Sunaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral-specific responses. Pediatrics* 1985; 75: 1011-1019.

39. *Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz CA, Marklund G, Rymo L, Wellinder C, Straus SE. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84: 570-574.*

40. *Miller G, Grogan E, Rowe D, Rooney C, Heston L, Eastman R, Andiman W, Niederman J, Lenoir G, Henle W, Sullivan J, Schooley R, Vossen J, Strauss S, Issekutz T. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis 1987; 156: 26-35.

41. *Evans AS, Niederman JC. Epstein-Barr virus. In: Evans AS, editor. Viral infection of humans, epidemiology and control. New York: Plenum Medical Book Company, 1982: 253-281.*

42. *Gärtnér BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol* 2003; 10: 78-82.

43. *Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol* 2004; 42: 3381-3387.

44. *Gärtnér BC, Kortmann K, Schäfer M, Mueller-Lantzsch N, Sester U, Kaul H, Pees H. No correlation in Epstein-Barr virus reactivation between serological parameters and viral load. J Clin Microbiol* 2000; 38: 2438.

45. *Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464.

46. *Deng H, Zeng Y, Lei Y, Zhao Z, Wang P, Li B, Pi Z, Tan B, Zheng Y, Pan W. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J (Engl) 1995; 108: 300-303.*

47. *Paul JR, Bunnell WW. The presence of heterophile antibodies in infectious mononucleosis. Am J Med Sci 1974; 267: 178-188.*

48. *Swahn A, Magnusson M, Jägda H, Schloss L, Kahlmeter G, Linde A. Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol* 1997; 35: 2728-2732.

49. *Kluttis JS, Wu AH, Smith A, Yen-Lieberman B, Gronowski AM. Diagnostic performance of a new automated heterophile antibody test in adults and children. Diagn Microbiol Infect Dis* 2008; 61: 351-353.

50. *Henle G, Henle W. Immunofluorescence in cells derived from Burkitt’s lymphoma. J Bacteriol 1966; 91: 1248-1256.*

51. *Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11: 499-520.*

52. *Linde A, Kallin B, Dillner I, Andersson J, Jägda H, Lindvall A, Wahren B. Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Clin Microbiol 1990; 161: 903-909.*

53. *Bruu AL, Hjeltland R, Holter E, Mortensen L, Natâs O, Petersen W, Skar AG, Skarpaa S, Tjade T, Asjo B. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol* 2000; 7: 451-456.

54. *de Ory F, Guisasola ME, Sanz JC, García-Bermejo I. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin Vaccine Immunol* 2011; 18: 444-448.

55. *Garetto F. Epstein-Barr Virus (EBV) VCA IgM, EBNA IgG, EBV IgM, EA IgG: an accurate diagnosis of the different stages of infection. LigandAssay 2005; 10: 64-65.*

56. *Marchetti D, Antonelli S, Deleonardi G, Grondana A, Casertano MG. Epstein-Barr virus infections and antibody panels.
effective for a correct infection diagnosis. In Proceeding of XXXVII National Congress AMCLI (Italian Association of Clinical Microbiology); 2008 Oct 5-8; Stresa, Italy

Schubert J, Zers W, Weisbrich B. Comparative evaluation of the use of immunobLOTS and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections. J Clin Virol 1998; 11: 161-172

Gärtner BC, Fischinger JM, Roemer K, Mak M, Fleurent B, Mueller-Lantzsch N. Evaluation of a recombinant line blot for diagnosis of Epstein-Barr Virus compared with ELISA, using immunofluorescence as reference method. J Virol Methods 2001; 93: 89-96

Werblin TP, Kim YT, Quaglia F, Siskind GW. Studies on the control of antibody synthesis. 3. Changes in heterogeneity of antibody affinity during the course of the immune response. Immunology 1973; 24: 477-492

Inouye S, Hasegawa A, Matsuno S, Katow S. Changes in antibody avidity after virus infections: detection by an immunorosentor assay in which a mild protein-denaturing agent is employed. J Clin Microbiol 1984; 20: 525-529

Kocks C, Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc Natl Acad Sci USA 1988; 85: 8206-8210

de Ory F, Antonaya J, Fernandez MV, Echevarria J. Application of low-avidity immunoglobulin G studies to diagnosis of Epstein-Barr virus infectious mononucleosis. J Clin Microbiol 1993; 31: 1669-1671

Andersson A, Vetter V, Kreutzer L, Bauer G. Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology. J Med Virol 1994; 43: 238-244

Gray JJ. Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation. J Virol Methods 1995; 52: 95-104

Wolter T, Gassmann C, Vetter V, Bauer G. Avidity determination: utilization of a basic immunological mechanism allows improvement of the serodiagnosis of infections. Clin Lab 1997; 43: 125-135

Weisbrich B. The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis. J Med Virol 1998; 54: 145-153

Robertson P, Beynon S, Whybín R, Brennan C, Vollmer-Conna U, Hickie I, Lloyd A. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. J Med Virol 2003; 70: 617-623

Recombi-Line EBV IgG Avidity. Instruction for use. Mikrogen, Germany, June 2008

Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132-136

Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5455

Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-1191

Steven's SJ, Verschuuren EA, Verkuiljen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-840

Macsween KF, Crawford DH. Epstein-Barr virus recent advances. Lancet Infect Dis 2003; 3: 131-140

Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant 2009; 9: 269-279

Chan KH, Ng MH, Seto WH, Peiris JS. Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection. J Clin Microbiol 2001; 39: 4152-4154

Luderer R, Kok M, Nieters HG, Schuurman R, de Weerdt O, Thijsen SF. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. Mol Diagn 2005; 19: 195-200

Hayden RT, Hokanson KM, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Val-Samakis A, Balfour HH. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol 2008; 46: 157-163

De Paoli P, Pratesi C, Bortolin MT. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 2007; 133: 809-815

Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006; 16: 251-261

Steven's SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfraccionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211-1216

Chan KC, Zhang J, Chan AT, Lei KJ, Leung SF, Chan LY, Chow KC, Lo YM. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63: 2028-2032

Gan VJ, Sullivan JL, Sibey JW. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis 1994; 170: 436-439

Ryan JL, Fan H, Swinnen LJ, Schichman SA, Raab-Traub N, Covington M, Elmore S, Gullely ML. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 2004; 13: 61-68

Ambinder RF, Lin L. Mononucleosis in the laboratory. J Infect Dis 2005; 192: 1503-1504

Yamamoto M, Kimura H, Hironaka T, Hiraï K, Hasegawa S, Kuzushima K, Shibata M, Morishima T. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases. J Clin Microbiol 1995; 33: 1765-1768

Bauer CC, Aberle SW, Popow-Kraupp T, Kapitan M, Hofmann H, Puchhammer-Stöckl E. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol 2005; 75: 54-58

Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. J Med Virol 2001; 64: 505-512

Kimura H, Nishikawa K, Hoshino Y, Soeuf A, Nishiyama Y, Morishima T. Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection. Med Microbiol Immunol 2000; 188: 197-202

Pitetti RD, Laus S, Wadowsky RM. Clinical evaluation of a quantitative real-time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children. Pediatr Infect Dis J 2003; 22: 736-739

Kimura H, Hoshino Y, Hara S, Nishikawa K, Sako M, Hi- rayama M, Komada Y, Morishima T. Viral load in Epstein-Barr virus-associated hemophagocytic syndrome. Microbiol Immunol 2002; 46: 379-382

Fafi-Kremer S, Verschuuren EA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-840

Balfour HH, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb CH, Cavert W, Wang DH, Brundage RC. A prospective clinical study of Epstein-Barr virus and host interactions during acute infec-
tious mononucleosis. J Infect Dis 2005; 192: 1505-1512

Hara S, Kimura H, Hoshino Y, Tanaka N, Nishikawa K, Ihira M, Yoshikawa T, Morishima T. Detection of herpesvirus DNA in the serum of immunocompetent children. Microbiol Immunol 1993; 37: 177-180

Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 190: 567-576

Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 2003; 41: 5419-5428

Gulley ML, Fan H, Elmore SH. Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting. J Mol Diagn 2006; 8: 589-597

Ikuta K, Saiga K, Deguchi M, Sairenji T. Epstein-Barr virus DNA is detected in peripheral blood mononuclear cells of EBV-seronegative infants with infectious mononucleosis-like symptoms. Virus Genes 2003; 26: 165-173

Health Protection Agency. Epstein-Barr virus serology - minimum testing algorithm. National Standard Method VSOP 26 Issue 3, 2008. Available from: URL: http://www.hpa-standardmethods.org.uk/pdf_sops.asp

Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005; 75: 59-69

Stevens SJ, Smits PH, Verkuijlen SA, Rockx DA, van Gorp EC, Mulder JW, Middeldorp JM. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 2007; 21: 2141-2149

Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevelveer G, Teyssié AR, Benetucci J, Picconi MA. Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis 2007; 11: 172-178

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665

Bauer G. The rational basis for efficient Epstein-Barr virus (EBV) serology. Clin Lab Med 1995; 41: 623-634

Horwitz CA, Henle W, Henle G, Schapiro R, Borken S, Bundzen R. Infectious mononucleosis in patients aged 40 to 72 years: report of 27 cases, including 3 without heterophil-antibody test reactivity. Pediatr Infect Dis J 1988; 7: 747-748

Kampmann M, Henninger K, Bauer G. Determination of antibodies directly specific against Epstein-Barr virus nuclear antigen-1 (EBNA-1) by anti-complementary immunofluorescence (ACIF). Med Microbiol Lett 1993; 2: 1-8

Vetter V, Kreutzer L, Bauer G. Differentiation of primary from secondary anti-EBNA-1-negative cases by determination of avidity of VCA-IgG. Clin Diagn Virol 1994; 2: 29-39

De Paschale M, Agrappi C, Manco MT, Mirri F, Viganò EF, Clerici P. Search for Anti-EBNA(D) Antibodies in Subjects with an “Isolated VCA IgG” Pattern. Int J Microbiol 2010; 2010: 695104

Sumaya CV. Endogenous reactivation of Epstein-Barr virus infections. J Infect Dis 1977; 135: 374-379

Nalesnik MA. Epstein-Barr virus. In: Lennette EH, Smith TF, editors. Laboratory diagnosis of viral infections. New York: Marcel Dekker Inc., 1999: 385-419

Obel N, Haier-Madsen M, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 1996; 104: 424-428

Wiedbrauk DL, Bassin S. Evaluation of five enzyme immunoassays for detection of immunoglobulin M antibodies to Epstein-Barr virus in viral capsid antigens. J Clin Microbiol 1993; 31: 1339-1341

Weber B, Brunner M, Preiser W, Doerr HW. Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus. J Virol Methods 1996; 57: 87-93

Matheson BA, Chisholm SM, Ho-Yen DO. Assessment of rapid ELISA test for detection of Epstein-Barr virus infection. J Clin Pathol 1990; 43: 691-693

Naveau S, Delfraissy JF, Poitrière A, Poyrand T, Chaput JC. [Simultaneous detection of IgM antibodies against the hepatitis A virus and the viral capsid antigen of Epstein-Barr virus in acute hepatitis]. Gastroentrol Clin Biol 1985; 9: 109-112

Rhodes G, Smith RS, Rubin RE, Vaughan J, Horwitz CA. Identical IgM antibodies recognizing a glycine-alanine epitope are induced during acute infection with Epstein-Barr virus and cytomegalovirus. J Clin Lab Anal 1990; 4: 456-464

Fikar CR, McKee C. False positivity of IGM antibody to Epstein-Barr virus capsid antigen during acute hepatitis A infection. Pediatr Infect Dis J 1994; 13: 413-414

Aalto SM, Linnanvaara K, Peltola H, Vuori E, Weissbrich B, Schubert J, Hedman L, Hedman K. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998; 56: 186-191

van Essen GG, Lieverse AG, Sprenger HG, Schirm J, Weiss J. False-positive Paul-Bunnell test in HIV seroconversion. Lancet 1988; 2: 747-748

Nystad TW, Myrøl H. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol 2007; 38: 292-297

Jensen IP, Vestergaard BF. Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Clin Diagn Virol 1997; 7: 133-137

Irving WL, Ratnamohan VM, Hueston LC, Chapman JR, Cunningham AL. Dual antibody rises to cytomegalovirus and human herpesvirus type 6: frequency of occurrence in CMV infections and evidence for genuine reactivity to both viruses. J Infect Dis 1990; 161: 910-916

Rosen A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature 1977; 267: 52-54

Oberender H, Straube E, Kunkel M, Gärtnert L, Morfiaadakis I. Epstein-Barr virus-specific immunoglobulin A in patients with infectious mononucleosis, an age-dependent factor. Eur J Clin Microbiol 1986; 5: 173-174

Hadari T, Margalith M, Saigiv E, Sarov B, Sarov I. The significance of serum IgM IgA and IgG antibodies specific for Epstein-Barr virus as determined by immunoperoxidase assay in the rapid diagnosis of infectious mononucleosis. Isr J Med Sci 1995; 31: 280-283

Akaboshi I, Katsuki T, Jamamoto J, Matsuda I. Unique pattern of Epstein-Barr virus specific antibodies in recurrent parotitis. Lancet 1983; 2: 1049-1051

Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear anti-
gen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435-438
131 Fleisher G, Bolognese R. Persistent Epstein-Barr virus infection and pregnancy. J Infect Dis 1983; 147: 982-986
132 Joncas J, Lapointe N, Gervais F, Leyritz M, Wills A. Unusual prevalence of antibodies to Epstein-Barr virus early antigen in ataxia telangiectasia. Lancet 1977; 1: 1160
133 Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004; 26: 598-602
134 Mazeron MC. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx]. Bull Cancer Radiother 1996; 83: 3-7
135 Shimakage M, Dezawa T, Chatani M. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up. Acta Otolaryngol 2000; 120: 100-104
136 Li S, Deng Y, Li X, Chen QP, Liao XC, Qin X. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J (Engl) 2010; 123; 1201-1205
137 Doer HW, Rentschler M, Scheifler G. Serologic detection of active infections with human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG subclass-specific antibodies. Infection 1987; 15: 93-98
138 Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol 1987; 21: 109-121
139 Winkelspecht B, Grasser F, Pees HW, Mueller-Lantzsch N. Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection. Arch Virol 1996; 141: 857-864
140 De Paschale M, Cagnin D, Manco MT, Clerici P. Significance of the “isolated EBNA-1 IgG” pattern in past EBV infection. Microbiol Med 2009; 24: 50-52

S- Editor Wang JL  L- Editor Ma JY  E- Editor Zheng XM